EVENTS · ARWR
PEERS
EARNINGS
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company that develops medicines for intractable diseases using RNA interference, a gene-silencing approach designed to reduce the production of disease-causing proteins. Arrowhead Pharmaceuticals focuses on therapeutic areas including cardiometabolic, liver, pulmonary, neuromuscular, complement-mediated, and central nervous system disorders. Its portfolio includes both commercial and clinical-stage programs built around its targeted RNAi platform, which is designed for tissue-specific delivery and precise gene suppression. The company works across product development, clinical research, and commercialization, with a pipeline that includes multiple investigational therapies aimed at genetically driven diseases. Arrowhead Pharmaceuticals serves the broader healthcare market by advancing treatments for complex conditions with limited options, positioning itself as a specialized player in RNA-based drug development.
Arrowhead Pharmaceuticals Refinances Term Loans With $400.0 Million Secured Facility
| Series | 1W | 1M |
|---|---|---|
| ARWR | +2.4% | +0.2% |
| Peers | +1.4% | +5.5% |
| Sector · Health Care | +5.7% | +13.6% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 37 | 26 |
| QUARTER | EPS EST | EPS ACTUAL | EPS SURPRISE | REACTION |
|---|---|---|---|---|
| Q3 FY2026 | −1.35 | −1.36 | −1.01% | — |
| Q2 FY2026 | −1.21 | −0.93 | +23.20% | — |
| Q1 FY2026 | 0.26 | 0.22 | −14.76% | — |
| Q4 FY2025 | −0.25 | −0.18 | +26.71% | — |
| Series | 1W | 1M |
|---|---|---|
| ARWR | +2.4% | +0.2% |
| Peers | +1.4% | +5.5% |
| Sector · Health Care | +5.7% | +13.6% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 37 | 26 |
